Colon cancer is a common preventable cancer. With the adoption of widespread colon
cancer screening in the developed countries, the incidence and mortality of colon cancer …

Despite lengthening survival, death rates from metastatic colorectal cancer (CRC) remain
unacceptably high, with a bright spot being the demonstration of durable responses in …

The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …

Colorectal cancer (CRC) represents the third cause of cancer‐related mortalities worldwide.
The progression of CRC to the metastatic phase significantly compromises the overall …

Following initial success in melanoma and lung tumours, immune checkpoint inhibitors
(ICIs) are now well recognized as a major immunotherapy treatment modality for multiple …

Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer
worldwide and clinical outcome has improved substantially during the last two decades with …

The success of immune checkpoint inhibitors (ICIs) in an increasing range of heavily
mutated tumor types such as melanoma has culminated in their exploration in different …

There are a wide range of therapies for metastatic colorectal cancer (CRC) available, but
outcomes remain suboptimal. Learning the role of the immune system in cancer …

Simple Summary The manuscript reports the most recent literature regarding treatment with
ICIs in mCRC, focusing on dMMR/MSI-H and POLE-mutated tumors, discussing current …

Importance Single-agent immune checkpoint inhibition has not shown activities in advanced
refractory colorectal cancer (CRC), other than in those patients who are microsatellite …